Relationship between glucagon-like peptide-1 receptor agonist use and incidence of trigger finger in patients with type 2 diabetes | Synapse
March 3, 2026
Relationship between glucagon-like peptide-1 receptor agonist use and incidence of trigger finger in patients with type 2 diabetes
Key Points
Trigger finger incidence is associated with the use of glucagon-like peptide-1 receptor agonists.
A 30% increase in trigger finger cases was observed in patients using GLP-1 agonists compared to those who did not.
Assessment of the correlation between glucagon-like peptide-1 receptor agonist use and trigger finger incidence involved data from diabetes management records.
These findings imply a need for monitoring trigger finger symptoms in patients receiving GLP-1 receptor agonist treatment.